St. Jude Reference #SJ-11-0014
A research team here at St. Jude, led by Howard Hughes Medical Investigator Brenda Schulman, PhD, have discovered a peptide that inhibits cullin neddylation, a process required for proper cell proliferation. It could be useful for drug screening and peptide screening applications; which could have therapeutic potential for treating cancer, inflammatory disorders and/or or pathogenic infections.
Peptide inhibitor, screening method, drug discovery, enzyme, cancer, pathogen, inflammation
Granted patents or published applications
An Issued US Patent application, 9,447,156; covers this peptide, its pharmaceutical use and screening methods for identifying additional inhibitors
Related scientific references
The research underlying this discovery was reported as Scott, D.C. et al., Science 334: 674-678 (Nov. 4, 2011).
We are currently seeking a corporate partner willing to commit their time and effort toward unlocking the therapeutic potential of this discovery. If you would like to learn more about this opportunity, please contact firstname.lastname@example.org at your earliest convenience.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.